EPRSQ Stock - EPIRUS Biopharmaceuticals, Inc.
Unlock GoAI Insights for EPRSQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.
Visit WebsiteEarnings History & Surprises
EPRSQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2016 | May 10, 2016 | $-0.54 | $-0.66 | -22.2% | ✗ MISS |
Q1 2016 | Mar 15, 2016 | $-0.56 | $-0.63 | -12.5% | ✗ MISS |
Q4 2015 | Nov 16, 2015 | $-0.51 | $-0.59 | -15.7% | ✗ MISS |
Q2 2015 | May 12, 2015 | $-0.42 | $-0.39 | +7.1% | ✓ BEAT |
Q1 2015 | Mar 23, 2015 | $-0.98 | $-0.80 | +18.4% | ✓ BEAT |
Q4 2014 | Nov 10, 2014 | $-0.43 | $-1.28 | -197.7% | ✗ MISS |
Q2 2014 | May 9, 2014 | $2.00 | $-1.50 | -175.0% | ✗ MISS |
Q1 2014 | Mar 13, 2014 | $-1.40 | $-2.90 | -107.1% | ✗ MISS |
Q4 2013 | Nov 4, 2013 | $-5.00 | $-4.60 | +8.0% | ✓ BEAT |
Q3 2013 | Aug 1, 2013 | $-3.90 | $-4.80 | -23.1% | ✗ MISS |
Q2 2013 | May 2, 2013 | $-4.05 | $-3.60 | +11.1% | ✓ BEAT |
Q1 2013 | Mar 6, 2013 | $-4.80 | $-3.60 | +25.0% | ✓ BEAT |
Q4 2012 | Nov 8, 2012 | $-4.65 | $-6.00 | -29.0% | ✗ MISS |
Q3 2012 | Aug 7, 2012 | $-6.48 | $-5.40 | +16.7% | ✓ BEAT |
Q2 2012 | May 3, 2012 | $-6.30 | $-7.80 | -23.8% | ✗ MISS |
Q1 2012 | Mar 7, 2012 | $-6.24 | $-6.60 | -5.8% | ✗ MISS |
Q4 2011 | Nov 2, 2011 | $-6.00 | $-5.40 | +10.0% | ✓ BEAT |
Q2 2011 | May 4, 2011 | $-5.60 | $-7.20 | -28.6% | ✗ MISS |
Q1 2011 | Mar 9, 2011 | $-7.20 | $-7.80 | -8.3% | ✗ MISS |
Q4 2010 | Nov 10, 2010 | $-6.60 | $-7.80 | -18.2% | ✗ MISS |
Latest News
Frequently Asked Questions about EPRSQ
What is EPRSQ's current stock price?
What is the analyst price target for EPRSQ?
What sector is EPIRUS Biopharmaceuticals, Inc. in?
What is EPRSQ's market cap?
Does EPRSQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EPRSQ for comparison